Our Pricing

How to Begin Mounjaro Treatment: Timing & First Steps

Understanding when to start Mounjaro UK treatment and how to prepare for your first injection can significantly improve your experience and outcomes. At Cured Pharmacy, our UK-registered clinical team guides patients through every step of starting tirzepatide therapy, from choosing the right injection time to managing the initial adjustment period with evidence-based protocols.

When to Start Mounjaro: Choosing Your First Injection Day

The best day to start Mounjaro depends on your weekly schedule and lifestyle commitments. Because tirzepatide is administered once weekly, selecting a consistent day that accommodates potential side effects during the first few weeks is essential for treatment adherence [1].

Most UK prescribers recommend starting on a Friday evening or Saturday morning, allowing you to rest at home during the weekend if you experience mild gastrointestinal symptoms common in the initial adjustment phase. The SURPASS-1 trial documented that approximately 20-25% of patients experienced transient nausea during the first two weeks, which typically resolved without intervention [1].

Once you've chosen your injection day, maintaining the same day each week optimises the medication's steady-state concentration in your system. If you need to adjust your schedule, you can move your injection day forward or backward by up to three days without compromising efficacy, though consistency produces the most predictable results [2].

Planning Around Life Events

Avoid starting Mounjaro immediately before important work commitments, social events, or travel. Allow at least one full week to assess your individual response before any significant obligations. Our superintendent pharmacist Tarun Kumar advises patients to complete their first injection when they have 48-72 hours of flexibility in their schedule, enabling proper rest and dietary adjustments if needed.

Optimal Injection Timing: Morning vs Evening

Mounjaro can be injected at any time of day, with or without food, but establishing a consistent time improves adherence and helps you remember your weekly dose [2]. Clinical trials did not demonstrate significant differences in efficacy based on injection timing, giving you flexibility to choose what works best for your routine.

Evening injections (between 6pm and 9pm) are preferred by many patients because any mild nausea or fatigue can occur during sleep. This timing also allows you to have eaten normally throughout the day, reducing the likelihood of injection-site reactions on an empty stomach.

Morning injections (between 7am and 10am) work well for patients who prefer to administer their medication at the start of their day and can monitor their response throughout waking hours. This approach provides the full day to maintain adequate hydration and adjust food intake if appetite changes occur.

Setting a Weekly Reminder

Use your smartphone calendar or medication tracking app to set a recurring weekly alert 30 minutes before your chosen injection time. This advance notice allows you to prepare your injection site, wash your hands thoroughly, and ensure your Mounjaro pen has reached room temperature after refrigeration—a step that reduces injection discomfort significantly.

Mounjaro Starting Dose Protocol in the UK

All patients beginning Mounjaro treatment in the UK start with the 2.5mg dose, regardless of their weight or previous medication history [1]. This initial dose serves as a tolerance-building phase, allowing your body to adapt to tirzepatide's dual GIP/GLP-1 receptor activation before escalating to therapeutic levels.

The standard UK dose escalation schedule, approved by the MHRA and supported by SURPASS trial data, follows a four-week increment pattern: 2.5mg for four weeks, then 5mg for four weeks, followed by 7.5mg, 10mg, 12.5mg, and finally 15mg if needed [1]. Your UK prescriber determines progression based on your weight loss response, tolerability, and clinical assessment at each stage.

Never skip the starting dose or attempt to accelerate the escalation schedule. The SURPASS-1 trial demonstrated that gradual dose increases reduced discontinuation rates due to gastrointestinal side effects by 40% compared to faster titration protocols [1]. This patient-centred approach maximises long-term adherence and treatment success.

What to Expect from the 2.5mg Starting Dose

The initial 2.5mg dose is sub-therapeutic for weight loss but produces measurable appetite reduction in most patients. You may notice decreased food cravings and earlier satiety within 3-5 days of your first injection. Average weight loss during the first four weeks typically ranges from 1-3% of baseline body weight, with more substantial reductions occurring as you progress to maintenance doses [2].

Preparing for Your First Mounjaro Injection

Before administering your first dose, remove your Mounjaro KwikPen from the refrigerator and allow it to reach room temperature for 30 minutes. Cold medication increases injection discomfort and can cause temporary skin irritation at the injection site. Never use external heat sources to warm the pen—room temperature equilibration is sufficient.

Select an injection site on your abdomen (at least 5cm away from your navel), upper thigh, or upper arm. The abdomen typically provides the most consistent absorption and is easiest for self-administration. Clean the area with an alcohol wipe and allow it to dry completely for 10 seconds before injecting to prevent stinging.

The KwikPen delivers a pre-measured dose automatically—you simply press the pen firmly against your skin and hold the button until you hear two clicks, indicating complete delivery. Keep the pen pressed against your skin for an additional 10 seconds after the second click to ensure the full dose has been administered. Remove the pen at the same angle you inserted it to minimise bruising.

Managing the First Week on Mounjaro

The first 7-10 days after starting Mounjaro require dietary mindfulness to minimise gastrointestinal side effects. Focus on smaller, more frequent meals rather than large portions, and prioritise protein-rich foods that provide sustained satiety. Avoid high-fat, spicy, or heavily processed foods during the initial adjustment period, as these can exacerbate nausea [2].

Maintain adequate hydration throughout your first week—aim for 2-2.5 litres of water daily, sipped consistently rather than consumed in large volumes. Proper hydration supports the medication's mechanism of action and reduces the severity of common side effects like constipation and headache.

Monitor your blood glucose if you have type 2 diabetes or prediabetes, as tirzepatide begins lowering glucose levels within 24-48 hours of your first injection. Contact your prescriber if you experience symptoms of hypoglycaemia (shakiness, sweating, confusion), particularly if you're taking other glucose-lowering medications that may require dose adjustment [1].

When to Contact Your UK Prescriber

Mild nausea, reduced appetite, and occasional loose stools are expected during the first two weeks and typically resolve without intervention. However, contact your UK prescriber immediately if you experience severe or persistent vomiting (more than 24 hours), signs of dehydration (dark urine, dizziness, rapid heartbeat), or severe abdominal pain that doesn't improve with rest [2].

Allergic reactions to tirzepatide are rare but require urgent medical attention. Seek immediate care if you develop difficulty breathing, facial swelling, rapid pulse, or widespread rash after your injection. These symptoms constitute a medical emergency and should be assessed at your nearest A&E department.

At Cured Pharmacy, our clinical team remains available via phone (+44 116 4646009) for any questions or concerns during your first month of treatment. We provide ongoing support throughout your dose escalation journey, ensuring you achieve optimal outcomes safely and comfortably. All Mounjaro prescriptions require clinical assessment by our UK-registered prescribers, who evaluate your suitability and provide personalised guidance at each treatment stage.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.